Roche agrees to acquire 89bio for about $3.5bn
MLex Summary: Basel, Switzerland-based pharmaceutical company Roche has agreed to acquire San Francisco-based 89bio, a clinical-stage biopharmaceutical company developing therapies for the treatment of liver and cardiometabolic diseases, for about $3.5...To view the full article, register now.
Already a subscriber? Click here to view full article